Recruiting

Observational Study

Sponsor:

University of Illinois at Chicago

Code:

NCT06206486

Conditions

Kidney Transplant Symptoms

Gut Microbiome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

no intervention, observational

Study Details

Brief summary:

Study Summary Nearly half (47%) of people with end-stage kidney disease (ESKD) whose kidney function is restored after kidney transplantation experience chronic pain compared to 19% of adults in the US general population. Pain is associated with comorbid fatigue, depression and anxiety, and withdrawal from usual physical and social activities; resulting in an inability to participate in and enjoy life. Severe pain can result in nonadherence to immunosuppression and treatment protocols and result in an increased risk of rejection, graft loss, and mortality. The role of symbiotic microbes (microbiota) in the gastrointestinal tract, and their functional genes (microbiome), is well established in diseases involving pain. Diet and stress play a major role in synthesis of signaling molecules critical to immunologic, metabolic, and endocrine pathways regulating chronic pain. Dietary patterns change dramatically after transplantation, as recipients move from a restricted "renal" diet to a regular diet, often resulting in increased consumption of foods high in sugars and fat. Moreover, psychological stress significantly impairs the function of the microbiome, initiating biological pathways involved in pain, leading to a disproportionate pain burden. Because the microbiome, serum metabolites, and pain are dynamic, our novel investigation will employ a prospective repeated measures design to interrogate the dynamic temporal relationships between the microbiome, metabolites associated with pathways regulating pain, transplantation factors (e.g. immunosuppression, kidney function), changing dietary patterns, and perceived stress, on pain scores before and after kidney transplantation. The investigators posit the gut microbiome, and its byproducts, may partially explain the underlying biological mechanisms of pain Interference in kidney disease. The investigators will address three aims: 1) To determine differential dynamic temporal relationships between microbial composition/functional genes and circulating serum metabolites in KTRs with pain vs no pain, 2) To determine the moderation effects of diet and perceived stress on dynamic temporal relationships between microbiome features, serum metabolites, and pain scores among KTRs, and 3) To use machine learning algorithms to identify host-microbial interactions that are causally linked to pain interference among KTRs. Because kidney function is restored, the kidney transplant model is powerful to study the longitudinal relationships between the microbiome, circulating metabolites and chronic pain in people with ESKD to develop patient-centered interventions to treat pain across the spectrum of CKD.

Conditions

Kidney Transplant Symptoms

Gut Microbiome

Study ID

NCT06206486

Start date

Oct 9, 2023

Status verified date

Apr, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Oct, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Receiving a kidney transplant at the University of Illinois Hospital \& Health Sciences System (UI Health) Transplant Center at the University of Illinois Chicago (UIC),
  • Planning to receive a kidney transplant at the UI Health Transplant Center
  • 18 years of age or older (adult), and
  • Understand the study process and provide written informed consent to participate.

Exclusion Criteria:

  • Having a history of colon cancer or an inflammatory bowel disease
  • Planning to receive a multiorgan transplant (e.g., simultaneous pancreas and kidney transplant).
  • Having a history of Clostridium difficile infection in the preceding 8 weeks.

Study Design

Enrollment

133 participants

Anticipated

Interventions and Outcome Measures

Interventions

no intervention, observational

This study is observational. No intervention description available.

Primary outcome measure

  • PROMIS [ Time Frame: baseline, 3 months, 6 months (T scores range form 0-100, higher scores indicate worse level of symptoms). ]

Central Contacts and Locations

Central contacts

Locations

UI Health

Recruiting

Chicago, Illinois, United States, 60612

Contacts

More Information

Sponsor

University of Illinois at Chicago

Last update posted

Aug 17, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Illinois at Chicago on 2026-08-17.